Rebecca A Haeusler1, Stefania Camastra1, Monica Nannipieri1, Brenno Astiarraga1, Jose Castro-Perez1, Dan Xie1, Liangsu Wang1, Manu Chakravarthy1, Ele Ferrannini1. 1. Department of Pathology and Cell Biology (R.A.H.), Columbia University, New York, New York 10032; Department of Clinical and Experimental Medicine (S.C., M.N., B.A., E.F.), University of Pisa School of Medicine, 56100 Pisa, Italy; Merck Research Laboratories (J.C.-P., D.X., L.W., M.C.), Cardiometabolic Disease, Kenilworth, New Jersey 07033; and CNR Institute of Clinical Physiology (E.F.), 56100 Pisa, Italy.
Abstract
CONTEXT: Alterations in bile acid (BA) synthesis and transport have the potential to affect multiple metabolic pathways in the pathophysiology of obesity. OBJECTIVE: The objective of the study was to investigate the effects of obesity on serum fluctuations of BAs and markers of BA synthesis. DESIGN: We measured BA fluctuations in 11 nonobese and 32 obese subjects and BA transporter expression in liver specimens from 42 individuals and specimens of duodenum, jejunum, ileum, colon, and pancreas from nine individuals. MAIN OUTCOME MEASURES: We analyzed serum BAs and markers of BA synthesis after overnight fasting, during a hyperinsulinemic-euglycemic clamp, or a mixed-meal tolerance test and the association of BA transporter expression with body mass index. RESULTS: BA synthesis markers were 2-fold higher (P < .01) and preferentially 12α-hydroxylated (P < .05) in obese subjects, and both measures were correlated with clamp-derived insulin sensitivity (r = -0.62, P < .0001, and r = -0.39, P = .01, respectively). Insulin infusion acutely reduced serum BAs in nonobese subjects, but this effect was blunted in obese subjects (δBAs -44.2% vs -4.2%, P < .05). The rise in serum BAs postprandially was also relatively blunted in obese subjects (δBAs +402% vs +133%, P < .01). Liver expression of the Na+-taurocholate cotransporting polypeptide and the bile salt export pump were negatively correlated with body mass index (r = -0.37, P = .02, and r = -0.48, P = .001, respectively). CONCLUSIONS: Obesity is associated with increased BA synthesis, preferential 12α-hydroxylation, and impaired serum BA fluctuations. The findings reveal new pathophysiological aspects of BA action in obesity that may lend themselves to therapeutic targeting in metabolic disease.
CONTEXT: Alterations in bile acid (BA) synthesis and transport have the potential to affect multiple metabolic pathways in the pathophysiology of obesity. OBJECTIVE: The objective of the study was to investigate the effects of obesity on serum fluctuations of BAs and markers of BA synthesis. DESIGN: We measured BA fluctuations in 11 nonobese and 32 obese subjects and BA transporter expression in liver specimens from 42 individuals and specimens of duodenum, jejunum, ileum, colon, and pancreas from nine individuals. MAIN OUTCOME MEASURES: We analyzed serum BAs and markers of BA synthesis after overnight fasting, during a hyperinsulinemic-euglycemic clamp, or a mixed-meal tolerance test and the association of BA transporter expression with body mass index. RESULTS:BA synthesis markers were 2-fold higher (P < .01) and preferentially 12α-hydroxylated (P < .05) in obese subjects, and both measures were correlated with clamp-derived insulin sensitivity (r = -0.62, P < .0001, and r = -0.39, P = .01, respectively). Insulin infusion acutely reduced serum BAs in nonobese subjects, but this effect was blunted in obese subjects (δBAs -44.2% vs -4.2%, P < .05). The rise in serum BAs postprandially was also relatively blunted in obese subjects (δBAs +402% vs +133%, P < .01). Liver expression of the Na+-taurocholate cotransporting polypeptide and the bile salt export pump were negatively correlated with body mass index (r = -0.37, P = .02, and r = -0.48, P = .001, respectively). CONCLUSIONS:Obesity is associated with increased BA synthesis, preferential 12α-hydroxylation, and impaired serum BA fluctuations. The findings reveal new pathophysiological aspects of BA action in obesity that may lend themselves to therapeutic targeting in metabolic disease.
Authors: Frédéric M Vaz; Coen C Paulusma; Hidde Huidekoper; Minke de Ru; Cynthia Lim; Janet Koster; Kam Ho-Mok; Albert H Bootsma; Albert K Groen; Frank G Schaap; Ronald P J Oude Elferink; Hans R Waterham; Ronald J A Wanders Journal: Hepatology Date: 2014-08-25 Impact factor: 17.425
Authors: P L Jansen; S S Strautnieks; E Jacquemin; M Hadchouel; E M Sokal; G J Hooiveld; J H Koning; A De Jager-Krikken; F Kuipers; F Stellaard; C M Bijleveld; A Gouw; H Van Goor; R J Thompson; M Müller Journal: Gastroenterology Date: 1999-12 Impact factor: 22.682
Authors: Carine Steiner; Alaa Othman; Christoph H Saely; Philipp Rein; Heinz Drexel; Arnold von Eckardstein; Katharina M Rentsch Journal: PLoS One Date: 2011-11-14 Impact factor: 3.240
Authors: Kristen E Syring; Travis J Cyphert; Thomas C Beck; Charles R Flynn; Nicholas A Mignemi; Owen P McGuinness Journal: Am J Physiol Endocrinol Metab Date: 2019-02-19 Impact factor: 4.310
Authors: Enrico Bertaggia; Kristian K Jensen; Jose Castro-Perez; Yimeng Xu; Gilbert Di Paolo; Robin B Chan; Liangsu Wang; Rebecca A Haeusler Journal: Am J Physiol Endocrinol Metab Date: 2017-04-04 Impact factor: 4.310
Authors: Tiara R Ahmad; Sei Higuchi; Enrico Bertaggia; Allison Hung; Niroshan Shanmugarajah; Nicole C Guilz; Jennifer R Gamarra; Rebecca A Haeusler Journal: J Biol Chem Date: 2020-07-20 Impact factor: 5.157